



**HAL**  
open science

## Characterization of transgenic mouse lines for selectively targeting satellite glial cells and macrophages in dorsal root ganglia

Yasmine Rabah  $\alpha$  , Bruna Rubino, Elsie Moukarzel, Cendra Agulhon

### ► To cite this version:

Yasmine Rabah  $\alpha$  , Bruna Rubino, Elsie Moukarzel, Cendra Agulhon. Characterization of transgenic mouse lines for selectively targeting satellite glial cells and macrophages in dorsal root ganglia. PLoS ONE, 2020. hal-03060384

**HAL Id: hal-03060384**

**<https://hal.science/hal-03060384v1>**

Submitted on 13 Dec 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## RESEARCH ARTICLE

# Characterization of transgenic mouse lines for selectively targeting satellite glial cells and macrophages in dorsal root ganglia

Yasmine Rabah<sup>1</sup>\*, Bruna Rubino<sup>1</sup>, Elsie Moukarzel<sup>1</sup>, Cendra Agulhon<sup>1</sup>\*

Integrative Neuroscience and Cognition Center (CNRS UMR8002), Glia-Glia & Glia-Neuron Interactions Laboratory, Faculty of Basic and Biomedical Sciences, Paris Descartes University, Paris, France

✉ These authors contributed equally to this work.

✉ Current address: Energy and Memory Laboratory, Brain Plasticity Unit, CNRS, ESPCI Paris, PSL Research University, Paris, France

\* [cendra.agulhon@parisdescartes.fr](mailto:cendra.agulhon@parisdescartes.fr)



## OPEN ACCESS

**Citation:** Rabah Y, Rubino B, Moukarzel E, Agulhon C (2020) Characterization of transgenic mouse lines for selectively targeting satellite glial cells and macrophages in dorsal root ganglia. PLoS ONE 15(9): e0229475. <https://doi.org/10.1371/journal.pone.0229475>

**Editor:** Eliseo A. Eugenin, University of Texas Medical Branch at Galveston, UNITED STATES

**Received:** February 5, 2020

**Accepted:** August 12, 2020

**Published:** September 11, 2020

**Copyright:** © 2020 Rabah et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the manuscript and its Supporting Information files.

**Funding:** This work was supported by a starting grant (Chair of Excellence) from the Foundation Ecole des Neurosciences de Paris (ENP), a European Marie Skłodowska-Curie career integration grant (# 334497), a DIM Cerveau & Pensée-Région Ile-de-France grant, as well as CNRS and Paris Descartes University financial support to CA. YR and EM were recipients of PhD

## Abstract

The importance of glial cells in the modulation of neuronal processes is now generally accepted. In particular, enormous progress in our understanding of astrocytes and microglia physiology in the central nervous system (CNS) has been made in recent years, due to the development of genetic and molecular toolkits. However, the roles of satellite glial cells (SGCs) and macrophages—the peripheral counterparts of astrocytes and microglia—remain poorly studied despite their involvement in debilitating conditions, such as pain. Here, we characterized in dorsal root ganglia (DRGs), different genetically-modified mouse lines previously used for studying astrocytes and microglia, with the goal to implement them for investigating DRG SGC and macrophage functions. Although SGCs and astrocytes share some molecular properties, most tested transgenic lines were found to not be suitable for studying selectively a large number of SGCs within DRGs. Nevertheless, we identified and validated two mouse lines: (i) a CreERT2 recombinase-based mouse line allowing transgene expression almost exclusively in SGCs and in the vast majority of SGCs, and (ii) a GFP-expressing line allowing the selective visualization of macrophages. In conclusion, among the tools available for exploring astrocyte functions, a few can be used for studying selectively a great proportion of SGCs. Thus, efforts remain to be made to characterize other available mouse lines as well as to develop, rigorously characterize and validate new molecular tools to investigate the roles of DRG SGCs, but also macrophages, in health and disease.

## Introduction

Astrocytes and microglia serve essential support and immune functions, and contribute to diseases of the CNS [1]. For a long time, their heterogeneity and roles in the CNS have remained unclear due to the lack of tools to specifically identify them, and monitor or alter their activity. However, over the last fifteen years, new genetically-encoded tools to selectively visualize

fellowships from the French Ministry of Research, and BR received a PhD fellowship from the European Union Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (# 66585). YR was awarded a master 2 fellowship from the Institute of Neuroscience and Cognition. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

astrocytes and microglia as well as read out or abolish astrocytic  $\text{Ca}^{2+}$  activity have been generated. They include (i) transgenic mice expressing green fluorescent protein (GFP) under the control of astrocytic or microglial promoters [2–5], (ii) transgenic mice expressing genetically-encoded  $\text{Ca}^{2+}$  indicators (GCaMP) to monitor astrocyte  $\text{Ca}^{2+}$  dynamics [6–8], or (iii)  $\text{IP}_3\text{R}2$  knockout mice to abolish global  $\text{G}_q$  protein-coupled receptor ( $\text{G}_q$  GPCR)-mediated  $\text{Ca}^{2+}$  elevations in astrocyte cell bodies and large processes [9,10]. These tools have been extremely useful for probing astrocyte and microglia functions in the CNS and are now extensively used in the field.

In the peripheral nervous system (PNS), SGCs in DRGs share several properties with astrocytes, including expression of cytosolic proteins [e.g. glial fibrillary acidic protein: GFAP [11]; S100 calcium-binding protein beta: S100 $\beta$  [12]; glutamine synthetase [13]], membrane neurotransmitter transporters [e.g. glutamate aspartate transporter: GLAST [13]], and channels [e.g. inwardly rectifying  $\text{K}^+$  channel 4.1 (Kir 4.1) [14]; connexin 43 (Cx43)-based gap junctions and hemichannels [15]]. As astrocytes and many other cell types, SGCs use  $\text{Ca}^{2+}$  as a signaling molecule [16]. Additionally, there is substantial evidence for a SGC role in chronic pain wherein SGCs undergo a reactive gliotic response accompanied with increased GFAP expression, hypertrophy, proliferation and upregulation of Cx43 [17,18]. Furthermore, the counterparts of CNS microglia in DRGs are the macrophages, and both express the ionized  $\text{Ca}^{2+}$ -binding adapter molecule 1 (Iba1) [19,20]. Emerging evidence has implicated the contribution of DRG macrophages to neuropathic pain development and axonal repair in the context of nerve injury [21–23]. Thus, understanding how SGC and macrophage morphology and function are remodeled in physiology and pathology can help to find new therapeutic targets for pain-related diseases [13,24–26]. However, SGC and macrophage heterogeneity and role remain largely unknown in DRGs, mainly due to the unavailability of tools to specifically visualize DRG glial cells and examine or manipulate their  $\text{Ca}^{2+}$  dynamics. Satellite glial cell or macrophage specific gene expression or deletion would therefore help to clarify the roles of those cells in DRGs.

To accomplish this, using immunohistochemistry or 2-photon  $\text{Ca}^{2+}$  imaging, we have characterized different available genetically-modified mouse lines widely used to study astrocytes or microglia. Our results showed that most lines used for examining astrocyte functions are very inefficient for studying selectively a large proportion of SGCs in DRGs. However, we have identified two mouse lines allowing either the selective expression of a  $\text{Ca}^{2+}$  biosensor in SGCs or the labelling of macrophages.

## Material and methods

### Animals

Mice were housed in transparent plastic cages (5 mice/cage) and fed *ad libitum*. Illumination was controlled automatically with a 12/12h light-dark cycle. S100 $\beta$ -eGFP [5], ALDH1L1-eGFP [27] and CX3CR1-eGFP [3] transgenic lines were used. Furthermore, CAG-lox-STOP-lox-GCaMP6f transgenic mouse line [7] was crossed with GLAST-CreERT2 [28], GFAP-Cre [29], Cx30-CreERT2 [28] or Cx43-CreERT2 [30] mice. As a result, we obtained four new double transgenic mouse lines that we named GLAST-CreERT2::GCaMP6f, GFAP-Cre::GCaMP6f, Cx30-CreERT2::GCaMP6f and Cx43-CreERT2::GCaMP6f. To induce expression of the  $\text{Ca}^{2+}$  biosensor GCaMP6f, GLAST-CreERT2::GCaMP6f and Cx30-CreERT2::GCaMP6 mice were injected intraperitoneally (i.p.) with tamoxifen (1 mg/day, Sigma) diluted in corn oil (Sigma) during 5 consecutive days. To obtain optimum GCaMP6f expression in brain astrocytes of Cx43-CreERT2::GCaMP6f mice, tamoxifen treatment lasted 10 days as previously described [31]. Animals were then used 2 weeks after the first day of treatment. All lines used were kept

heterozygous for transgenes encoding GFP/eGFP, GCaMP6f, Cre or CreERT2. Experiments were conducted in 2 to 3 month-old male and female mice from the C57BL/6J background. Animal care and procedures were carried out according to the guidelines set out in the European Community Council Directives. The protocol was approved by the Committee on the Ethics of Animal Experiments of Paris Descartes University (Protocol Number: 2018061412588713).

### Immunohistochemistry, image acquisition and analysis

Animals were transcardially perfused with 4% paraformaldehyde under ketamine/xylazine (100 mg/kg– 10 mg/kg respectively, i.p.) anesthesia. Brains and lumbar L3, L4 and L5 DRGs were removed, post-fixed for 24 h or 2 h in 4% paraformaldehyde, respectively. Then, tissues were cryoprotected overnight at 4°C in 0.02 M phosphate buffer saline (PBS, pH 7.4) containing 20% sucrose, and frozen in optimal cutting temperature compound. Sixteen or 14 µm thick sections (brain or DRG, respectively) were cut using a cryostat (Leica), mounted on Superfrost glass slides and stored at -80°C. The day of the experiment, sections were washed 3 times for 15 min each in 0.02 M PBS. Sections were incubated overnight in 0.02 M PBS containing 0.3% Triton X100, 0.02% sodium azide and primary antibodies (Table 1) at room temperature in a humid chamber. In order to readily identify fine subcellular compartments expressing GFP/eGFP or GCaMP6f and to not miss any transgene expression, GFP/eGFP/GCaMP6f signal was amplified using an antibody directed against GFP. Of note, GFP/eGFP/GCaMP6f signal was visible without such amplification. The following day, sections were washed 3 times for 15 min each in 0.02 M PBS, and incubated for 2 h at room temperature with secondary antibodies diluted in 0.02 M PBS containing 0.3% Triton X100 and 0.02% sodium azide. Then, sections were washed 3 times for 15 min in 0.02 M PBS and mounted between slide and coverslip using Vectashield medium containing DAPI (Vector Laboratories). Negative controls, *i.e.* slices incubated with secondary antibodies only, were used to set criteria (gain, exposure time) for image acquisition in each experiment. Image acquisition was performed with an Axio Observer Z1 epifluorescence Zeiss microscope, an ORCA Flash 2.8 million pixel camera, and a PlanNeoFluar 20x/0.5NA objective. Images were extracted using the ZEN 2011 blue edition software (Zeiss). Cell counting measurements were performed

**Table 1. List of primary and secondary antibodies with corresponding dilutions used in the current study.**

Antibodies	Species	Company/Cat. #	Dilution (DRG & V1)
Anti-CD68	Rat	Serotec/MCA1957	1:2000
Anti-GFAP	Rabbit	Dako/Z0334	1:5000
Anti-GFAP	Chicken	Abcam/ab4674	1:1000
Anti-GFP	Chicken	Invitrogen/A10262	1:1000
Anti-GLAST	Rabbit	Frontier Institute/Af660	1:5000
Anti-Iba1	Rabbit	Wako/019-1974	1:2500 (DRG) 1:1000 (V1)
Anti-NeuN	Guinea Pig	Millipore/ABN90	1:1000
Anti-NF	Rabbit	Millipore/AB9568	1:1000
Anti-S100β	Rabbit	Abcam/ab52642	1:1000
Alexa Fluor® 488 anti-chicken	Goat	Invitrogen/A-11039	1:1000
Alexa Fluor® 546 anti-guinea pig	Goat	Invitrogen/A-11074	1:1000
Alexa Fluor® 546 anti-rabbit	Goat	Invitrogen/A-11035	1:1000
Alexa Fluor® 546 anti-rat	Goat	Invitrogen/A-11081	1:1000

<https://doi.org/10.1371/journal.pone.0229475.t001>

using manual cell counting plugin function in ImageJ software (National Institutes of Health, USA). Cells were counted on 3–4 mice/genotype, 3 brain slices/mouse (positive control) and 8–15 DRG slices/mouse. The total numbers of counted cells for the 3–4 mice/genotype are presented in Tables 1 and 2. Because it was difficult to discriminate individual SGCs within the several SGCs surrounding a single neuronal cell body, “rings” surrounding individual neuronal cell bodies were quantified..

## Calcium imaging

Acute intact DRG preparations were prepared from GFAP-Cre::GCaMP6f mice. Briefly, vertebrae and dura mater were removed and lumbar L4 and L5 DRGs were exposed and immediately covered with ice cold (slushy) incubation ACSF solution (95 mM NaCl, 1.9 mM KCl, 1.2 mM KH<sub>2</sub>PO<sub>4</sub>, 0.5 mM CaCl<sub>2</sub>, 7 mM MgSO<sub>4</sub>, 26 mM NaHCO<sub>3</sub>, 15 mM glucose, 50 mM sucrose) and bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. DRGs were incubated for 30 min at 35°C in the incubation solution and then left to recover for 1 h 30 min at room temperature. A single DRG was placed in the recording chamber of a custom-built 2-photon laser-scanning microscope with a 20x water immersion objective (x20/0.95w XLMPPlanFluor, Olympus). GCaMP6f was excited at 920 nm with a Ti:Sapphire laser (Mai Tai HP; Spectra-Physics). DRGs were continuously superfused at a rate of 4 ml/min with recording solution (127 mM NaCl, 1.9 mM KCl, 1.2 mM KH<sub>2</sub>PO<sub>4</sub>, 2.4 mM CaCl<sub>2</sub>, 1.3 mM MgSO<sub>4</sub>, 26 mM NaHCO<sub>3</sub>, 15 mM glucose) and bubbled with 95% O<sub>2</sub>–5% CO<sub>2</sub>. To evoke intracellular Ca<sup>2+</sup> elevations in DRG GCaMP6f-expressing cells, a cocktail of agonists to endogenous G<sub>q</sub> GPCRs containing 50 μM DHPG (Abcam), 10 μM histamine (Sigma Aldrich), 10 μM carbachol (Abcam), and 50 μM ATP (Sigma Aldrich) was bath applied for 30 sec.

**Table 2. Data quantification in DRG SGCs and V1 astrocytes from the mouse lines used in the current study.**

DORSAL ROOT GANGLIA							
Mouse lines	Nbr of mice, Nbr of slices/mouse	Total NeuN+ or NF+ neurons	Total GFP+ or G6+ neurons	% of GFP+ or G6+ neurons	Total GLAST+SGCs	Total GFP+ or G6+ SGCs	% of GFP+ or G6+ SGCs
S100β-eGFP	3, 10	599	81	13.5	345	296	85.8
ALDH1L1-eGFP	3, 11	1002	72	7.2	571	322	56.4
GFAP-Cre::GCaMP6f	3, 14	1189	696	58.5	1250	22	1.8
GLAST-CreERT2::GCaMP6f	4, 15	1148	44	3.8	892	48	5.4
Cx30-CreERT2::GCaMP6f	3, 8	837	0	0	721	0	0
Cx43-CreERT2::GCaMP6f	3, 9	433	31	4.0	363	336	92.6
VISUAL CORTEX							
Mouse lines	Nbr of mice, Nbr of slices/mouse	Total NeuN+ neurons	Total GFP+ or G6+ neurons	% of GFP+ or G6+ neurons	Total S100β+astrocytes	Total GFP+ or G6+ astrocytes	% of GFP+ or G6+ astrocytes
S100β-eGFP	3, 10	4737	1	0.02	1288	1108	86.0
ALDH1L1-eGFP	3, 8	7807	0	0	1360	1117	82.1
GLAST-CreERT2::GCaMP6f	3, 9	9533	3	0.03	1267	713	56.3
Cx30-CreERT2::GCaMP6f	3, 9	5343	5	0.1	1000	464	46.4
Cx43-CreERT2::GCaMP6f	3, 9	5203	227	4.4	780	74	9.5

Abbreviations: G6, GCaMP6f; GFP, green fluorescent protein; Nbr, number; NF, neurofilament.

<https://doi.org/10.1371/journal.pone.0229475.t002>


## Results

### Transgenic mouse lines for investigating the distribution and morphology of sgcs and macrophages

*S100 $\beta$ -eGFP mice exhibit eGFP expression in both SGCs and sensory neurons.* S100 $\beta$  protein is a commonly used astrocytic marker in the brain and spinal cord and has also been reported to be a marker of SGCs in DRGs [12,32]. The S100 $\beta$ -eGFP transgenic mouse [5], which expresses enhanced GFP (eGFP) under the control of the S100 $\beta$  promoter, has proved to be a useful tool to selectively label almost all astrocytes [32,33]. In the primary visual cortex (V1), we found that eGFP was expressed in 86% of astrocytes (Fig 1A; Table 2) and only marginally (0.02%) in neurons (Fig 1B; Table 2), corroborating those previous studies. This mouse line appears also to be valuable for labeling SGCs within DRGs, since eGFP immunoreactivity was detected in 85.8% of SGCs as shown by the colocalization of eGFP with GLAST, a specific SGC marker (Fig 2A; Table 2). In addition, some cells expressing eGFP, and exhibiting a typical feature of non-myelinating Schwann cells, were found in nerves attached to DRGs (Fig 2C; Table 2); this is expected for cells known to synthesize S100 $\beta$  [34,35]. However, 13.5% of sensory neuron soma (Fig 2B; Table 2) and their corresponding axons (Fig 2C) were found to express eGFP. To test whether this unexpected neuronal eGFP expression reflected normal endogenous S100 $\beta$  protein expression in DRGs of wildtype mice, we used an antibody directed against S100 $\beta$ . S100 $\beta$  endogenous protein was detected in both DRG SGCs and neurons of wildtype mice (S1 Fig), in agreement with the eGFP expression pattern observed in S100 $\beta$ -eGFP mice. Hence, the S100 $\beta$  promoter does not represent a valuable promoter to target transgene expression selectively in DRG SGCs. However, it does allow eGFP expression in the vast majority of DRG SGCs.


*ALDH1L1-eGFP mice express eGFP in a subset of SGCs and some neurons.* Another recently discovered marker of astrocytes is the protein aldehyde dehydrogenase 1 family member L1 [aldh1l1; [2]]. The ALDH1L1 promoter has been used to generate several transgenic mouse lines [2,8,36], including the ALDH1L1-eGFP mice that exhibit eGFP selectively in most astrocytes of the CNS [2]. In agreement, we found that eGFP is expressed in 82.1% of V1 astrocytes (Fig 3A; Table 2) with no detectable expression in neurons (Fig 3B; Table 2). The distribution of eGFP-expressing cells was then investigated in DRGs of ALDH1L1-eGFP mice. Enhanced GFP immunoreactivity was observed only in 56.4% of SGCs (Fig 4A; Table 2) as well as in a low percentage (7.2%) of sensory neuron soma, making this transgenic line unsuitable for the specific visualization of the majority of SGCs.

*CX3CR1-eGFP mice show specific eGFP expression in macrophages.* The CX3C chemokine receptor 1 (CX3CR1), known as the fractalkine receptor [3], is a marker of microglial cells [37,38]. The CX3CR1-eGFP mouse line, expressing eGFP under the control of the CX3CR1 promoter [3], has been extremely useful to visualize microglial cells and dynamic changes in their morphology. In support of this previous study, we found a selective eGFP expression in 99.5% of V1 microglial cells with no detectable expression in neurons (Fig 5A and 5B; Table 3). Since microglial cells are the CNS resident macrophages, we reasoned that peripheral macrophages should also express eGFP in DRGs from CX3CR1-GFP mice. Indeed, we observed that eGFP was expressed in 90.9% of Iba1-expressing macrophages (Fig 6A; Table 3), validating the use of the CX3CR1-eGFP mouse line for labeling a prominent number of DRG macrophages and investigating their morphological remodeling. Note that a few eGFP-positive elements did not express Iba1 (Fig 6A, arrow). Because Iba1-immunopositive profiles are spotty and not found within the whole cytosol, but instead are localized in some subcellular compartments of macrophages, such eGFP-positive elements might correspond to Iba1-negative macrophage compartments.



**Fig 1. Expression of eGFP in S100 $\beta$ -eGFP mouse brain.** A, B, Representative images of immunohistochemistry in the primary visual cortex (V1) from S100 $\beta$ -eGFP mice showing eGFP-expressing cells (A & B left, green), S100 $\beta$ -expressing astrocytes (A middle, red, arrowheads), and NeuN-expressing neurons (B middle, red, asterisks). A & B right show superimposed pictures. In A & B, bottom panel images correspond to higher magnification images. For each row, scale bar in left picture applies to middle and right corresponding pictures. Abbreviations: ec, external capsule; CA1, subfield 1 of Ammon's horn; I-VI, layers of V1.

<https://doi.org/10.1371/journal.pone.0229475.g001>






**Fig 2. Expression of eGFP in S100 $\beta$ -eGFP mouse DRGs.** A, B, Representative images of immunohistochemistry in DRGs from S100 $\beta$ -eGFP mice showing eGFP-expressing cells (A-C left, green), GLAST-expressing SGCs (A middle, red, arrowheads), and neurofilament-expressing neurons (B middle, red, asterisks). C, Images of proximal DRG nerves showing eGFP staining (C left, green), non-myelinating Schwann cells (C left, arrows) and neurofilament-expressing axons (C middle, arrowheads). A-C right show superimposed pictures. In A-C, bottom panel images correspond to enlargements of boxed areas in top panel images. For each row, scale bar in left picture applies to middle and right corresponding pictures.

<https://doi.org/10.1371/journal.pone.0229475.g002>


### Mouse lines for investigating the roles of SGC Ca<sup>2+</sup> signaling

*GFAP-Cre::GCaMP6f mouse line expresses GCaMP6f Ca<sup>2+</sup> biosensor mainly in DRG sensory neurons.* Emerging evidence showing that Ca<sup>2+</sup> is an important signaling messenger in SGCs [12,39,40] prompted us to search for molecular tools to probe SGC Ca<sup>2+</sup> dynamics. To do so, we took advantage of the powerful CAG-lox-STOP-lox-GCaMP6f transgenic mouse line [7] that was recently developed to express the genetically-encoded Ca<sup>2+</sup> indicator GCaMP6f in cell types of interest. We first crossed CAG-lox-STOP-lox-GCaMP6f mice with GFAP-Cre mice [29] to generate GFAP-Cre::GCaMP6f double transgenic mice. GFAP is indeed extensively used as a gold standard astrocytic marker, which expression is enhanced in reactive astrocytes during aging, CNS injury, pain, and diseases [41]. GFAP has also been reported as a marker of DRG SGCs [11], although we have not found convincing immunohistochemical evidence in the literature showing clear SGC GFAP expression under physiological conditions. In agreement, in our hands, immunohistochemical experiments conducted on DRGs from wildtype



**Fig 3. Expression of eGFP in ALDH1L1-eGFP mouse brain.** A, B, Representative images of immunohistochemistry in V1 from ALDH1L1-eGFP mice showing eGFP-expressing cells (A & B left, green), S100 $\beta$ -expressing astrocytes (A middle, red, arrowheads), and NeuN-expressing neurons (B middle, red, asterisks). A & B right show superimposed pictures. For each row, scale bar in left picture applies to middle and right corresponding pictures.

<https://doi.org/10.1371/journal.pone.0229475.g003>




**Fig 4. Expression of eGFP in ALDH1L1-eGFP mouse DRGs.** A, B, Representative images of immunohistochemistry in DRGs from ALDH1L1-eGFP mice showing eGFP-expressing cells (A & B left, green), GLAST-expressing SGCs (A middle, red, arrowheads), and NeuN-expressing neurons (B middle, red, asterisks). A & B right show superimposed pictures. In A & B, bottom panel images correspond to enlargements of boxed areas in top panel pictures. In A bottom row, boxed area has been rotated by about 45° clockwise. For each row, scale bar in left picture applies to middle and right corresponding pictures.

<https://doi.org/10.1371/journal.pone.0229475.g004>

mice using two different antibodies directed against GFAP (Table 1) have revealed almost no GFAP-expressing SGCs (data not shown). However, a large number of studies have shown increases in SGC GFAP expression level under pathological conditions, including, peripheral nerve injury, DRG compression and pain [17,24].

In the CNS, GFAP is known to be expressed in neural progenitors during developmental stages, giving rise to neurons, astrocytes and oligodendrocytes, thus preventing the use of the non-inducible GFAP-Cre mice and Cre-LoxP system to selectively study astrocytes [29,42–44]. The observation that astrocytes, neurons, and neuropil from V1 GFAP-Cre::GCaMP6f expressed GCaMP6f (Fig 7A and 7B) was consistent with those previous studies and the view that recombination occurs during development. However, because SGCs derive from the neural crest, a different lineage than astrocytic lineage, there was a possibility that GFAP-Cre mice could be useful to drive gene expression selectively in a great proportion of SGCs. In DRGs from GFAP-Cre::GCaMP6f mice, GCaMP6f was expressed in only 1.8% of SGCs while, to our surprise, it was observed in 58.5% of sensory neurons (including small- and large-sized



**Fig 5. Expression of eGFP in CX3CR1-eGFP mouse brain.** A, B, Representative images of immunohistochemistry in V1 from CX3CR1-eGFP mice showing eGFP-expressing cells (A & B left, green), Iba1-expressing microglial cells (A middle, red, arrowheads), and NeuN-expressing neurons (B middle, red, asterisks). A & B right show superimposed pictures. For each row, scale bar in left picture applies to middle and right corresponding pictures.

<https://doi.org/10.1371/journal.pone.0229475.g005>

Table 3. Data quantification in DRG macrophages and V1 microglial cells from the CX3CR1-eGFP mouse line.

DORSAL ROOT GANGLIA							
Mouse line	Nbr of mice, Nbr of slices/mouse	Total NeuN + neurons	Total GFP + neurons	% of GFP + neurons	Total Iba1 + macrophages	Total GFP + macrophages	% of GFP + macrophages
CX3CR1-eGFP	3, 8	689	0	0	320	291	90.9
VISUAL CORTEX							
Mouse line	Nbr of mice, Nbr of slices/mouse	Total NeuN + neurons	Total GFP + neurons	% of GFP + neurons	Total Iba1 + microglia	Total GFP + microglia	% of GFP + microglia
CX3CR1-eGFP	3, 8	2488	0	0	851	847	99.5


Abbreviations: GFP, green fluorescent protein; Nbr, number.

<https://doi.org/10.1371/journal.pone.0229475.t003>

diameter neurons; Fig 8A; Table 2). To assess whether GCaMP6f was expressed under detectable levels in SGCs, SGC functional  $Ca^{2+}$  signals were registered using 2-photon imaging in intact *ex vivo* DRGs. Bath application of an agonist cocktail to  $G_q$  GPCRs did not evoke any  $Ca^{2+}$  elevations in cells morphologically identified as SGCs (*i.e.* ring-shaped cells surrounding neuronal soma). However, 23.5% of GCaMP6f-expressing sensory neurons exhibited marked intracellular  $Ca^{2+}$  elevations (Fig 8B). Taken together these results show that the GFAP-Cre::GCaMP6f double transgenic mouse line is not an adequate tool for studying  $Ca^{2+}$  dynamics selectively in DRG SGCs.

*GLAST-CreERT2::GCaMP6f and Cx30-CreERT2::GCaMP6f mice express GCaMP6f in a few or no SGCs, respectively.* GLAST has been conventionally used to identify a subset of astrocytes and the majority of DRG SGCs [45–47], making the GLAST promoter a good candidate to target gene expression in a large number of SGCs. Additionally, connexin 30 (Cx30) has also been used as a marker of a fraction of astrocytes [45], although its expression in DRG SGCs has not yet been reported. To determine whether GLAST and Cx30 promoters could drive GCaMP6f expression selectively in SGCs, we crossed both inducible GLAST-CreERT2 [28] and Cx30-CreERT2 [28] mice with CAG-lox-STOP-lox-GCaMP6f mice. To induce GCaMP6f expression in the resultant GLAST-CreERT2::GCaMP6f and Cx30-CreERT2::GCaMP6f double transgenic lines, mice were treated with 1 mg tamoxifen per day during 5 consecutive days. As expected, in the CNS (V1), GCaMP6f was detected in 56.3% and 46.4% of astrocytes, in these two lines respectively (Fig 9A; Fig 10A; Table 2) with an insignificant expression in neurons (0.03% and 0.1%, respectively; Fig 9B; Fig 10B; Table 2). In contrast, DRGs from GLAST-CreERT2::GCaMP6f mice showed GCaMP6f immunoreactivity in only 5.4% of SGCs and a low percentage (3.8%) of sensory neurons (Fig 11A and 1B; Table 2), invalidating this mouse line for investigating  $Ca^{2+}$  dynamics selectively in SGCs. Furthermore, no GCaMP6f expression at all was found in SGCs or sensory neurons of Cx30-CreERT2::GCaMP6f (Fig 12A and 12B; Table 2), making this mouse line unsuitable to study  $Ca^{2+}$  signaling in DRG SGCs. Surprisingly though, GCaMP6f was observed in non-identified cells, which occasionally expressed macrophage markers (Fig 12C), suggesting that a few of them are macrophages. Of note, GCaMP6f was also found to be expressed at the DRG surface, possibly in tissues encapsulating DRGs (Fig 12B).

*Cx43-CreERT2::GCaMP6f mouse line allows the detection of  $Ca^{2+}$  transients in the vast majority of SGCs.* Cx43 is a widely used specific marker of a large proportion of CNS astrocytes and almost all DRG SGCs [13,48], making it particularly relevant to astrocyte and SGC research. In another attempt to establish a tool for monitoring  $Ca^{2+}$  transients selectively in a great number of SGCs, we generated the inducible Cx43-CreERT2::GCaMP6f double transgenic mouse line by crossing the tamoxifen-inducible Cx43-CreERT2 [30] with the CAG-lox-STOP-lox-GCaMP6f mice [7]. Two weeks after tamoxifen treatment, V1 cortex and DRGs




**Fig 6. Expression of eGFP in CX3CR1-eGFP mouse DRGs.** A, B, Representative images of immunohistochemistry in DRGs from CX3CR1-eGFP mice showing eGFP staining (A & B left, green, arrowheads), Iba1 staining (A middle, red, arrowheads), and neurons identified by NeuN immunoreactivity (B

middle, red, asterisks). In **A bottom panel**, the arrow points to an eGFP-expressing element that does not colocalize with Iba1 staining. **A & B right** show superimposed pictures. In **A & B**, bottom panel images correspond to higher magnification images. For each row, scale bar in left picture is applied to middle and right corresponding pictures.

<https://doi.org/10.1371/journal.pone.0229475.g006>


were analyzed. To our disappointment, GCaMP6f immunoreactivity was observed in only 9.5% of V1 astrocytes (**Fig 13A; Table 2**), a much lower percentage than previously reported in hippocampal astrocytes (~70%; [31]). Possible explanations for these discrepancies are regional (V1 versus hippocampus) variability in transgene recombination efficiency, in addition to the fact that we tested our mice 2 weeks after tamoxifen treatment compared to 4 weeks [31]. Furthermore, GCaMP6f was also detectable in a small subset (4.4%) of neurons (**Fig 13B; Table 2**). These results suggest that Cx43-CreERT2 mouse line may be ineffective for driving substantial GCaMP6f expression specifically in V1 astrocytes, even when treating mice 10 times (10 x 1 mg/kg tamoxifen) as previously reported [31].

However, and importantly, cellular immunohistochemical characterization in DRGs revealed that GCaMP6f was expressed in 92.6% of SGCs and a very small subset (4%) of neurons (**Fig 14A and 14B; Table 2**). In conclusion, the inducible Cx43-CreERT2::GCaMP6f line can be used to study the role of Ca<sup>2+</sup> activity in the majority of DRG SGCs. We believe that this mouse line will prove to be a valuable tool to examine DRG SGC functions.



**Fig 7. Expression of GCaMP6f in GFAP-Cre::GCaMP6f mouse brain.** **A, B**, Representative images of immunohistochemistry in V1 from GFAP-Cre::GCaMP6f mice showing GCaMP6f ubiquitous expression (**A & B left**, green), S100β-expressing astrocytes (**A middle**, red, arrowheads), and NeuN-expressing neurons (**B middle**, red, asterisks). **A & B right** show superimposed pictures. For each row, scale bar in left picture applies to middle and right corresponding pictures.

<https://doi.org/10.1371/journal.pone.0229475.g007>




**Fig 8. Cellular expression and functionality of GCaMP6f in GFAP-Cre::GCaMP6f mouse DRGs.** A, Representative images of immunohistochemistry in DRGs from GFAP-Cre::GCaMP6f mice showing GCaMP6f staining (top & bottom left panels, green), GLAST-expressing SGCs (top middle panel, red, arrowheads), and small and large sensory neurons (bottom middle panel, red, asterisks). Top & bottom right panels show superimposed pictures. For each row, scale bar in left picture applies to middle and right corresponding pictures. B, Representative images of 2-photon Ca<sup>2+</sup> imaging experiment in *ex vivo* DRGs where neuronal GCaMP6f-expressing cell bodies (outlined areas of interest, left panel) exhibit intracellular Ca<sup>2+</sup> increases; ① baseline, ② G<sub>q</sub> GPCR agonist cocktail (50 μM ATP, 10 μM Histamine, 10 μM Carbachol and 50 μM DHPG) application, and ③ wash (right panel).

<https://doi.org/10.1371/journal.pone.0229475.g008>

## Discussion

In this study we report the characterization of several tools for investigating SGC and macrophage morphological changes as well as Ca<sup>2+</sup> activity within DRGs. Our data show that most tested transgenic mice widely used to investigate astrocyte morphology and function are not suitable for studying DRG SGCs. Indeed, among these mice, some exhibit ectopic transgene expression in small to large proportions of neurons while others show low to no transgene expression in SGCs.




**Fig 9. Expression of GCaMP6f in GLAST-CreERT2::GCaMP6f mouse brain.** A, B, Representative images of immunohistochemistry in V1 from GLAST-CreERT2::GCaMP6f mice showing GCaMP6f-expressing cells (A & B left, green, arrowheads), S100β-expressing astrocytes (A middle, red, arrowheads), and NeuN-expressing neurons (B middle, red, asterisks). A & B right show superimposed pictures. For each row, scale bar in left picture applies to middle and right corresponding pictures.

<https://doi.org/10.1371/journal.pone.0229475.g009>

However, we generated and identified a double transgenic line, named Cx43-CreERT2::GCaMP6f, allowing inducible GCaMP6f expression primarily in the vast majority of DRG SGCs (92.6%) with only a very small percentage (4%) of neurons expressing GCaMP6f. Considering the high GCaMP6f expression level detected in SGCs, ectopic CreERT2-mediated recombination in neurons might be easily reduced by simply decreasing the number of tamoxifen injections (< 10 injections) as well as time post-treatment (< 15 days). Although it would be of interest to test whether GCaMP6f is detectable in other DRG cell types, including Schwann cells, fibroblasts, pericytes and endothelial cells, this possibility seems unlikely based on (i) the peculiar and readily identifiable SGC shape (ring surrounding round neurons), (ii) the fact that no GCaMP6f expression was observed in nerves attached to DRG, and (iii) the fact that drug-induced  $Ca^{2+}$  elevations were observed exclusively in ring-shaped cells surrounding neuronal cell bodies from the Cx43-CreERT2::GCaMP6f (data not shown). With the emerging interest in SGC  $Ca^{2+}$  signaling in modulating nociceptive neuron activity [39,40,49], this new line should be applicable for investigating a wide array of questions in pain research. Additionally, it is worth pointing out that Cx43 expression is very stable and even upregulated in SGCs following PNS injury. Therefore we do not anticipate any compromised (downregulated) transgene expression using the Cx43-CreERT2 mouse line, strengthening the likely applicability of this mouse line for a wide array of questions in PNS neurobiology and pain research. Interestingly, a publication from Valeria Cavalli's laboratory was recently posted on BioRxiv and reported a mouse line (BLBPCre-ERT2) allowing conditional expression of transgenes specifically in SGCs, complementing the use of the Cx43-CreERT2 mouse line. Furthermore, we identified a second mouse line, called CX3CR1-eGFP, displaying eGFP expression selectively in most DRG macrophages. This line is likely to be useful for the study of spinal






**Fig 10. Expression of GCaMP6f in Cx30-CreERT2::GCaMP6f mouse brain.** A, B, Representative images of immunohistochemistry in V1 from Cx30-CreERT2::GCaMP6f mice showing GCaMP6f-expressing cells (A & B left, green, arrowheads), S100β-expressing astrocytes (A middle, red, arrowheads), and NeuN-expressing neurons (B middle, red, asterisks). A & B right show superimposed pictures. For each row, scale bar in left picture applies to middle and right corresponding pictures.

<https://doi.org/10.1371/journal.pone.0229475.g010>

cord injury in which abnormal pain strongly correlates with an increased number of DRG macrophages [50].

Among the other mouse lines we characterized, S100β-eGFP line may be considered applicable to some extent, even though eGFP was expressed in a substantial percentage of sensory neurons (13.5%), but also in a great proportion of DRG SGCs (85.8%). The readily identifiable ring-shaped SGCs can indeed be almost undoubtedly differentiated from the rounded neuronal cell bodies. Additionally, eGFP expression was found to be brighter in SGCs relatively to neuronal cell bodies (Fig 2A and 2B), which helps ascertain the identity of both cell types. Of note, we found that eGFP expression in SGCs and neurons reflects the endogenous S100β protein expression, showing that, in DRGs, S100β is not a glial selective promoter. These data complement studies reporting that S100β promoter drives transgene expression in some motor neurons within the brainstem and spinal cord [33,51].

The fact that the GFAP promoter drives merely no transgene expression in SGCs from GFAP-Cre::GCaMP6f mouse line is consistent with our immunohistochemistry data showing only rare GFAP-expressing SGCs. Furthermore, our data showing Cre-mediated recombination in 58.5% of sensory neurons in such GFAP-Cre::GCaMP6f mice suggest the possibility that GFAP is expressed in DRG neuronal lineage during development. This possibility though is not supported by the absence of evidence for a developmental GFAP expression in PNS neuronal lineage, while such expression is well described in the CNS [52]. Thus, together our results suggest that the GFAP promoter used in the GFAP-Cre::GCaMP6f mice is not




**Fig 11. Expression of GCaMP6f in GLAST-CreERT2::GCaMP6f mouse DRGs.** A, B, Representative images of immunohistochemistry in DRGs from GLAST-CreERT2::GCaMP6f mice showing GCaMP6f labeling (A & B left, green), GLAST-expressing SGCs (A bottom panel, red, arrowheads), and

NeuN-expressing neurons (**B bottom panel**, red, asterisks). **A & B right** show superimposed pictures. In **A & B**, bottom panel images correspond to higher magnification images. For each row, scale bar in left picture applies to middle and right corresponding pictures.


<https://doi.org/10.1371/journal.pone.0229475.g011>

sufficient to drive a strong and selective expression of transgenes in a large number of SGCs under physiological conditions. However, in disagreement of this hypothesis, the same promoter (2.2kB human GFAP minimum promoter, 29) has been previously used successfully to highly express a transgene selectively in the overwhelming majority of DRG SGCs with no




**Fig 12. Expression of GCaMP6f in Cx30-CreERT2::GCaMP6f mouse DRGs.** A–C, Representative images of immunohistochemistry in DRGs from Cx30-CreERT2::GCaMP6f mice showing GCaMP6f immunoreactivity (A–C left, green, arrowheads), GLAST-expressing SGCs (A middle, red), and NeuN-expressing neurons (B middle, red, asterisks). In B left, empty arrows point to GCaMP6f expression at the surface of the DRG. In C left, white arrow points to GCaMP6f staining that colocalizes with the macrophage marker CD68 immunoreactivity (C middle, red.). A–B right show superimposed pictures. For each row, scale bar in left picture applies to middle and right corresponding pictures.

<https://doi.org/10.1371/journal.pone.0229475.g012>



**Fig 13. Expression of GCaMP6f in Cx43-CreERT2::GCaMP6f mouse brain.** A, B, Representative images of immunohistochemistry in V1 from Cx43-CreERT2::GCaMP6f mice showing GCaMP6f immunoreactivity (A & B left, green), S100 $\beta$ -expressing astrocytes (A middle bottom panel, red, arrowheads) and NeuN-expressing neurons (B bottom panel, red, asterisk). A & B right show superimposed pictures. In A & B, bottom panel pictures correspond to enlargements of top panel pictures. For each row, scale bar in left picture applies to middle and right corresponding pictures.

<https://doi.org/10.1371/journal.pone.0229475.g013>



**Fig 14. Expression of GCaMP6f in Cx43-CreERT2::GCaMP6f mouse DRGs.** A, B, Representative images of immunohistochemistry in DRGs from Cx43-CreERT2::GCaMP6f mice showing GCaMP6f immunoreactivity (A & B left, green), GLAST-expressing SGCs (A middle, red, arrowheads), and NF-expressing neuronal cell bodies (B middle, red, asterisks). Note: Yellow asterisk (A, top panel) shows a single neuron expressing GCaMP6f. A & B right show superimposed pictures. In A & B, bottom panel pictures correspond to enlargements of boxed areas in top panel images. For each row, scale bar in left picture applies to middle and right corresponding pictures.

<https://doi.org/10.1371/journal.pone.0229475.g014>

ectopic sensory neuronal expression [53]. This implies that other factors (e.g. number of transgene copies, gene microenvironment) may account for the variability of transgene expression levels in SGCs and cell selectivity. Indeed, transgenes insert randomly into the genome and the transgene expression cannot always mimic endogenous promoter activity. Thus, controlling gene microenvironment represents a strategy to enhance the specificity of transgenic targeting. One approach is to insert transgenes into a cassette containing all introns, promoter regulatory elements, exons and 5' and 3' flanking DNA of the GFAP gene [52]. This approach has been used in a recent study showing specific transgene expression in SGCs of the trigeminal ganglia, although it remains to be evaluated in DRG SGCs [49]. Another approach is to insert transgenes into bacterial artificial chromosomes (BACs) as they reduce the influence of chromosome position effects and allow more predictable transgene expression patterns. Despite these advantages, BAC transgenic mice appear to suffer from some remaining expression variation. Indeed, using the BAC-based GLAST-CreERT2 mice [28] to generate the GLAST-CreERT2::GCaMP6f mice, we obtained both (i) a marginal percentage of GLAST-driven CreERT2-mediated recombination in DRG SGCs, and (ii) a lack of cell specificity, while endogenous GLAST protein is selectively and prominently expressed in essentially all SGCs [47]. Therefore, it stands to reason that even though both, conventional and BAC-based transgenesis, can lead to robust and cell specific transgene expression in the CNS glial cells, their expression pattern may significantly differ in DRG glia (and *vice versa*). Knock-in technology may be considered as a good alternative to traditional transgenic techniques; indeed it enables transgene insertion at a specific glial gene locus of the mouse genome, which allows excellent control of gene microenvironment, and thus is likely to better avoid chromosome position effects and circumvent the above-discussed drawbacks associated with conventional and BAC-based transgenesis. Our findings using the knock-in CX3CR1-eGFP mouse line does support the relevance of this approach by showing specific eGFP expression in the vast majority of microglial cells and macrophages in V1 and DRGs, respectively (Fig 5; Fig 6). Thus, to improve DRG glial cell specific targeting, it would be of interest in future studies to generate and/or use knock-in glial mouse models. One of such mouse models, the knock-in GLAST-CreERT2 mouse line in which CreERT2 transgene is inserted at the GLAST gene locus [54], appears to be a good candidate to examine next.

A large number of *in vivo* studies have used the GFAP or S100 $\beta$  promoters to drive different transgene expression in astrocytes. Results from these studies are routinely interpreted as due to the expression of transgenes only in astrocytes. Our finding that the GFAP or S100 $\beta$  promoters drive GCaMP6f or eGFP expression in 58.8% or 13.5% of DRG sensory neurons, respectively, should be considered when interpreting *in vivo* results from such studies.

In conclusion, most of the tools tested in the current study were found ineffective in studying selectively the majority of SGCs in DRGs, although a lot of molecular and functional similarities exist between DRG SGCs and astrocytes. Therefore, further work is required for characterizing and identifying other already available tools as well as developing new genetically-modified mouse lines and adeno-associated viral tools to specifically target large proportions of DRG SGCs, but also macrophages. Together with the two mouse lines validated here (Cx43-CreERT2::GCaMP6f and CX3CR1-eGFP), these future molecular tools will be of prominent interest in understanding better how DRG glia can modulate sensory information processing under physiological and pathological conditions.

## Supporting information

**S1 Fig. S100 $\beta$  immunoreactivity signal (red) in DRGs from wildtype mice, showing that endogenous S100 $\beta$  is expressed in both ring-shaped SGCs (arrowheads) and sensory**

neuron cell bodies (asterisks).  
(PDF)

## Acknowledgments

We gratefully acknowledge S. Antoine and S. Guinoiseau for animal care; S. Guinoiseau and P. Meriau for dissecting some tissues; C. Ayissi Sama and M. Tantouch for slicing some tissues; J. M. Andrieu, F. Charbonnier, B. Delhomme, P. Djian, and M. Oheim for sharing lab spaces and pieces of equipment (cryostat, microscopes); J. Strinnakre for proof reading; and both the BioMedTech imaging and mouse core facilities.

## Author Contributions

**Conceptualization:** Yasmine Rabah, Elsie Moukarzel, Cendra Agulhon.

**Data curation:** Yasmine Rabah, Bruna Rubino, Elsie Moukarzel, Cendra Agulhon.

**Formal analysis:** Yasmine Rabah, Bruna Rubino, Elsie Moukarzel.

**Funding acquisition:** Yasmine Rabah, Bruna Rubino, Elsie Moukarzel, Cendra Agulhon.

**Investigation:** Yasmine Rabah, Bruna Rubino, Elsie Moukarzel.

**Methodology:** Cendra Agulhon.

**Project administration:** Cendra Agulhon.

**Resources:** Cendra Agulhon.

**Supervision:** Cendra Agulhon.

**Validation:** Bruna Rubino, Elsie Moukarzel, Cendra Agulhon.

**Visualization:** Yasmine Rabah, Bruna Rubino, Cendra Agulhon.

**Writing – original draft:** Yasmine Rabah, Cendra Agulhon.

**Writing – review & editing:** Bruna Rubino, Elsie Moukarzel, Cendra Agulhon.

## References

1. Barres BA. Neuron Perspective The Mystery and Magic of Glia: A Perspective on Their Roles in Health and Disease. *Neuron*. 2008; 60(3):430–40. <https://doi.org/10.1016/j.neuron.2008.10.013>; PMID: 18995817
2. Yang Y, Vidensky S, Jin L, Jie C, Lorenzini I, Frankl M, et al. Molecular comparison of GLT1+ and ALDH1L1+ astrocytes in vivo in astroglial reporter mice. *Glia*. 2011; 59(2):200–7. <https://doi.org/10.1002/glia.21089>; PMID: 21046559
3. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. *Mol Cell Biol*. 2000; 20(11):4106–14. <https://doi.org/10.1128/mcb.20.11.4106-4114.2000>; PMID: 10805752
4. Zhuo L, Sun B, Zhang C-L, Fine A, Chiu S-Y, Messing A. Live Astrocytes Visualized by Green Fluorescent Protein in Transgenic Mice. *Dev Biol*. 1997; 187(1):36–42. <https://doi.org/10.1006/dbio.1997.8601>; PMID: 9224672
5. Zuo YY, Lubischer JL, Kang H, Tian L, Mikesh M, Marks A, et al. Fluorescent proteins expressed in mouse transgenic lines mark subsets of glia, neurons, macrophages, and dendritic cells for vital examination. *J Neurosci*. 2004; 24(49):10999–1009. <https://doi.org/10.1523/JNEUROSCI.3934-04.2004>; PMID: 15590915
6. Zariwala HA, Borghuis BG, Hoogland TM, Madisen L, Tian L, De Zeeuw CI, et al. A Cre-Dependent GCaMP3 Reporter Mouse for Neuronal Imaging In Vivo. *J Neurosci*. 2012; 32(9):3131–41. <https://doi.org/10.1523/JNEUROSCI.4469-11.2012>; PMID: 22378886

7. Madisen L, Garner AR, Shimaoka D, Chuong AS, Klapoetke NC, Li L, et al. Transgenic Mice for Intersectional Targeting of Neural Sensors and Effectors with High Specificity and Performance. *Neuron*. 2015; 85(5):942–58. <https://doi.org/10.1016/j.neuron.2015.02.022>; PMID: 25741722
8. Srinivasan R, Lu T-Y, Chai H, Xu J, Huang BS, Golshani P, et al. New Transgenic Mouse Lines for Selectively Targeting Astrocytes and Studying Calcium Signals in Astrocyte Processes In Situ and In Vivo. *Neuron*. 2016; 92(6):1181–95. <https://doi.org/10.1016/j.neuron.2016.11.030>; PMID: 27939582
9. Petravicz J, Fiacco TA, McCarthy KD. Loss of IP3 Receptor-Dependent Ca<sup>2+</sup> Increases in Hippocampal Astrocytes Does Not Affect Baseline CA1 Pyramidal Neuron Synaptic Activity. *J Neurosci*. 2008; 28(19):4967–73. <https://doi.org/10.1523/JNEUROSCI.5572-07.2008>; PMID: 18463250
10. Agulhon C, Fiacco TA, McCarthy KD. Hippocampal short- and long-term plasticity are not modulated by astrocyte Ca<sup>2+</sup> signaling. *Science*. 2010; 327(5970):1250–4. <https://doi.org/10.1126/science.1184821>; PMID: 20203048
11. Woodham P, Anderson PN, Nadim W, Turmaine M. Satellite cells surrounding axotomized rat dorsal root ganglion cells increase expression of a GFAP-like protein. *Neurosci Lett*. 1989; 98(1):8–12. [https://doi.org/10.1016/0304-3940\(89\)90364-9](https://doi.org/10.1016/0304-3940(89)90364-9); PMID: 2710403
12. Hanani M. Satellite glial cells in sensory ganglia: from form to function. *Brain Res Brain Res Rev*. 2005; 48(3):457–76. <https://doi.org/10.1016/j.brainresrev.2004.09.001>; PMID: 15914252
13. Ohara PT, Vit J-P, Bhargava A, Romero M, Sundberg C, Charles AC, et al. Gliopathic pain: when satellite glial cells go bad. *Neuroscientist*. 2009; 15(5):450–63. <https://doi.org/10.1177/1073858409336094>; PMID: 19826169
14. Vit J-P, Ohara PT, Bhargava A, Kelley K, Jasmin L. Silencing the Kir4.1 potassium channel subunit in satellite glial cells of the rat trigeminal ganglion results in pain-like behavior in the absence of nerve injury. *J Neurosci*. 2008; 28(16):4161–71. <https://doi.org/10.1523/JNEUROSCI.5053-07.2008>; PMID: 18417695
15. Retamal MA, Riquelme MA, Stehberg J, Alcayaga J. Connexin43 Hemichannels in Satellite Glial Cells, Can They Influence Sensory Neuron Activity? *Front Mol Neurosci*. 2017; 10:374. <https://doi.org/10.3389/fnmol.2017.00374>; PMID: 29200997
16. Gu Y, Chen Y, Zhang X, Li G-W, Wang C, Huang L-YM. Neuronal soma-satellite glial cell interactions in sensory ganglia and the participation of purinergic receptors. *Neuron Glia Biol*. 2010; 6(1):53–62. <https://doi.org/10.1017/S1740925X10000116>; PMID: 20604979
17. Donegan M, Kernisant M, Cua C, Jasmin L, Ohara PT. Satellite glial cell proliferation in the trigeminal ganglia after chronic constriction injury of the infraorbital nerve. *Glia*. 2013; 61(12):2000–8. <https://doi.org/10.1002/glia.22571>; PMID: 24123473
18. Ledda M, Blum E, De Palo S, Hanani M. Augmentation in gap junction-mediated cell coupling in dorsal root ganglia following sciatic nerve neuritis in the mouse. *Neuroscience*. 2009; 164(4):1538–45. <https://doi.org/10.1016/j.neuroscience.2009.09.038>; PMID: 19778588
19. Kwon MJ, Shin HY, Cui Y, Kim H, Thi AH Le, Choi JY, et al. CCL2 Mediates Neuron-Macrophage Interactions to Drive Proregenerative Macrophage Activation Following Preconditioning Injury. *J Neurosci*. 2015; 35(48):15934–47. <https://doi.org/10.1523/JNEUROSCI.1924-15.2015>; PMID: 26631474
20. Imai Y, Kohsaka S. Intracellular signaling in M-CSF-induced microglia activation: role of Iba1. *Glia*. 2002; 40(2):164–74. <https://doi.org/10.1002/glia.10149>; PMID: 12379904
21. Miura T, Mitsunaga S, Ikeda M, Ohno I, Takahashi H, Kuwata T, et al. Neural invasion spreads macrophage-related allodynia via neural root in pancreatic cancer. *Anesth Analg*. 2018; 126(5):1729–38. <https://doi.org/10.1213/ANE.0000000000002803>; PMID: 29570153
22. Simeoli R, Montague K, Jones HR, Castaldi L, Chambers D, Kelleher JH, et al. Exosomal cargo including microRNA regulates sensory neuron to macrophage communication after nerve trauma. *Nat Commun*. 2017; 8(1):1778. <https://doi.org/10.1038/s41467-017-01841-5>; PMID: 29176651
23. Isami K, Imai S, Sukeishi A, Nagayasu K, Shirakawa H, Nakagawa T, et al. The impact of mouse strain-specific spatial and temporal immune responses on the progression of neuropathic pain. *Brain Behav Immun*. 2018; 74:121–32. <https://doi.org/10.1016/j.bbi.2018.08.013>; PMID: 30171890
24. Ji R-R, Berta T, Nedergaard M. Glia and pain: is chronic pain a gliopathy? *Pain*. 2013; 154 Suppl:S10–28. <https://doi.org/10.1016/j.pain.2013.06.022>; PMID: 23792284
25. Calvo M, Dawes JM, Bennett DLH. The role of the immune system in the generation of neuropathic pain. *The Lancet Neurology*. 2012. [https://doi.org/10.1016/S1474-4422\(12\)70134-5](https://doi.org/10.1016/S1474-4422(12)70134-5); PMID: 22710756
26. Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. *J Neuroimmunol*. 2010; 229(1–2):26–50. <https://doi.org/10.1016/j.jneuroim.2010.08.013>; PMID: 20870295



27. Yang Y, Vidensky S, Jin L, Jie C, Lorenzini I, Frankl M, et al. Molecular comparison of GLT1+ and ALDH1L1+ astrocytes in vivo in astroglial reporter mice. *Glia*. 2011; 59(2):200–7. <https://doi.org/10.1002/glia.21089>; PMID: 21046559
28. Slezak M, Göritz C, Niemiec A, Frisé J, Chambon P, Metzger D, et al. Transgenic mice for conditional gene manipulation in astroglial cells. *Glia*. 2007; 55(15):1565–76. <https://doi.org/10.1002/glia.20570>; PMID: 17823970
29. Casper KB, McCarthy KD. GFAP-positive progenitor cells produce neurons and oligodendrocytes throughout the CNS. *Mol Cell Neurosci*. 2006; 31(4):676–84. <https://doi.org/10.1016/j.mcn.2005.12.006>; PMID: 16458536
30. Eckardt D, Theis M, Degen J, Ott T, van Rijen HVM, Kirchhoff S, et al. Functional role of connexin43 gap junction channels in adult mouse heart assessed by inducible gene deletion. *J Mol Cell Cardiol*. 2004; 36(1):101–10. <https://doi.org/10.1016/j.yjmcc.2003.10.006>; PMID: 14734052
31. Gosejacob D, Dublin P, Bedner P, Hüttmann K, Zhang J, Tress O, et al. Role of astroglial connexin30 in hippocampal gap junction coupling. *Glia*. 2011; 59(3):511–9. <https://doi.org/10.1002/glia.21120>; PMID: 21264956
32. Raponi E, Agenes F, Delphin C, Assard N, Baudier J, Legraverend C, et al. S100B expression defines a state in which GFAP-expressing cells lose their neural stem cell potential and acquire a more mature developmental stage. *Glia*. 2007; 55(2):165–77. <https://doi.org/10.1002/glia.20445>; PMID: 17078026
33. Vives V, Alonso G, Solal AC, Joubert D, Legraverend C. Visualization of S100B-positive neurons and glia in the central nervous system of EGFP transgenic mice. *J Comp Neurol*. 2003; 457(4):404–19. <https://doi.org/10.1002/cne.10552>; PMID: 12561079
34. Mata M, Alessi D, Fink DJ. S100 is preferentially distributed in myelin-forming Schwann cells. *J Neurocytol*. 1990; 19(3):432–42. <https://doi.org/10.1007/bf01188409>; PMID: 2391542
35. Fujiwara S, Hoshikawa S, Ueno T, Hirata M, Saito T, Ikeda T, et al. SOX10 transactivates S100B to suppress Schwann cell proliferation and to promote myelination. *PLoS One*. 2014; 9(12):e115400. <https://doi.org/10.1371/journal.pone.0115400>; PMID: 25536222
36. Tso CF, Simon T, Greenlaw AC, Puri T, Mieda M, Herzog ED. Astrocytes Regulate Daily Rhythms in the Suprachiasmatic Nucleus and Behavior. *Curr Biol*. 2017; 27(7):1055–61. <https://doi.org/10.1016/j.cub.2017.02.037>; PMID: 28343966
37. Garcia JA, Cardona SM, Cardona AE. Analyses of Microglia Effector Function Using CX3CR1-GFP Knock-In Mice. In: *Methods in molecular biology* ( Clifton, NJ). 2013. p. 307–17. [https://doi.org/10.1007/978-1-62703-520-0\\_27](https://doi.org/10.1007/978-1-62703-520-0_27); PMID: 23813389
38. Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, Lafaille JJ, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. *Cell*. 2013; 155(7):1596–609. <https://doi.org/10.1016/j.cell.2013.11.030>; PMID: 24360280
39. Zhang X, Chen Y, Wang C, Huang L-YM. Neuronal somatic ATP release triggers neuron-satellite glial cell communication in dorsal root ganglia. *Proc Natl Acad Sci U S A*. 2007; 104(23):9864–9. <https://doi.org/10.1073/pnas.0611048104>; PMID: 17525149
40. Chen Y, Zhang X, Wang C, Li G, Gu Y, Huang L-YM. Activation of P2X7 receptors in glial satellite cells reduces pain through downregulation of P2X3 receptors in nociceptive neurons. *Proc Natl Acad Sci U S A*. 2008; 105(43):16773–8. <https://doi.org/10.1073/pnas.0801793105>; PMID: 18946042
41. Sofroniew M V., Vinters H V. Astrocytes: biology and pathology. *Acta Neuropathol*. 2010; 119(1):7–35. <https://doi.org/10.1007/s00401-009-0619-8>; PMID: 20012068
42. Anthony TE, Klein C, Fishell G, Heintz N. Radial glia serve as neuronal progenitors in all regions of the central nervous system. *Neuron*. 2004; [https://doi.org/10.1016/S0896-6273\(04\)00140-0](https://doi.org/10.1016/S0896-6273(04)00140-0); PMID: 15046721
43. Malatesta P, Hartfuss E, Götz M. Isolation of radial glial cells by fluorescent-activated cell sorting reveals a neuronal lineage. *Development*. 2000; 127(24):5253–63.
44. Miyata T, Kawaguchi A, Okano H, Ogawa M. Asymmetric inheritance of radial glial fibers by cortical neurons. *Neuron*. 2001; [https://doi.org/10.1016/S0896-6273\(01\)00420-2](https://doi.org/10.1016/S0896-6273(01)00420-2); PMID: 11567613
45. Karpuk N, Burkovetskaya M, Fritz T, Angle A, Kielian T. Neuroinflammation leads to region-dependent alterations in astrocyte gap junction communication and hemichannel activity. *J Neurosci*. 2011; 31(2):414–25. <https://doi.org/10.1523/JNEUROSCI.5247-10.2011>; PMID: 21228152
46. Berger U V, Hediger MA. Distribution of the glutamate transporters GLAST and GLT-1 in rat circumventricular organs, meninges, and dorsal root ganglia. *J Comp Neurol*. 2000; 421(3):385–99. [https://doi.org/10.1002/\(sici\)1096-9861\(20000605\)421:3<385::aid-cne7>3.0.co;2-s](https://doi.org/10.1002/(sici)1096-9861(20000605)421:3<385::aid-cne7>3.0.co;2-s); PMID: 10813794
47. Carozzi VA, Canta A, Oggioni N, Ceresa C, Marmiroli P, Konvalinka J, et al. Expression and distribution of “high affinity” glutamate transporters GLT1, GLAST, EAAC1 and of GCP11 in the rat peripheral

- nervous system. *J Anat.* 2008; 213(5):539–46. <https://doi.org/10.1111/j.1469-7580.2008.00984.x>; PMID: 19014361
48. Rouach N, Avignone E, Mème W, Koulakoff A, Venance L, Blomstrand F, et al. Gap junctions and connexin expression in the normal and pathological central nervous system. *Biol cell.* 2002; 94(7–8):457–75. [https://doi.org/10.1016/s0248-4900\(02\)00016-3](https://doi.org/10.1016/s0248-4900(02)00016-3); PMID: 12566220
  49. Hanstein R, Hanani M, Scemes E, Spray DC. Glial pannexin1 contributes to tactile hypersensitivity in a mouse model of orofacial pain. *Sci Rep.* 2016; 6(1):38266. <https://doi.org/10.1038/srep38266>; PMID: 27910899
  50. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. *Cell.* 2009; 139(2):267–84. <https://doi.org/10.1016/j.cell.2009.09.028>; PMID: 19837031
  51. Atkin SD, Patel S, Kocharyan A, Holtzclaw LA, Weerth SH, Schram V, et al. Transgenic mice expressing aameleon fluorescent Ca<sup>2+</sup> indicator in astrocytes and Schwann cells allow study of glial cell Ca<sup>2+</sup> + signals in situ and in vivo. *J Neurosci Methods.* 2009; 181(2):212–26. <https://doi.org/10.1016/j.jneumeth.2009.05.006>; PMID: 19454294
  52. Garcia ADR, Doan NB, Imura T, Bush TG, Sofroniew M V. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. *Nat Neurosci.* 2004; 7(11):1233–41. <https://doi.org/10.1038/nn1340>; PMID: 15494728
  53. Agulhon C, Boyt KM, Xie AX, Friocourt F, Roth BL, McCarthy KD. Modulation of the autonomic nervous system and behaviour by acute glial cell G<sub>q</sub> protein-coupled receptor activation *in vivo*. *J Physiol.* 2013; 591(22):5599–609. <https://doi.org/10.1113/jphysiol.2013.261289>; PMID: 24042499
  54. Mori T, Tanaka K, Buffo A, Wurst W, Kühn R, Götz M. Inducible gene deletion in astroglia and radial glia—a valuable tool for functional and lineage analysis. *Glia.* 2006; 54(1):21–34. <https://doi.org/10.1002/glia.20350>; PMID: 16652340